Literature DB >> 20150305

Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.

N Z Hobbs1, J Barnes, C Frost, S M D Henley, E J Wild, K Macdonald, R A Barker, R I Scahill, N C Fox, S J Tabrizi.   

Abstract

BACKGROUND AND
PURPOSE: Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease.
MATERIALS AND METHODS: Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age.
RESULTS: Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P < .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P < .0001); ventricular volume was 9.27 mL larger (P < .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P < .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P < .001), and accelerated with disease duration (P = .02).
CONCLUSIONS: We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology.

Entities:  

Mesh:

Year:  2010        PMID: 20150305      PMCID: PMC7963924          DOI: 10.3174/ajnr.A2018

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  20 in total

1.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

2.  Defective emotion recognition in early HD is neuropsychologically and anatomically generic.

Authors:  Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Jason D Warren; Chris Frost; Rachael I Scahill; Gerard R Ridgway; David G MacManus; Roger A Barker; Nick C Fox; Sarah J Tabrizi
Journal:  Neuropsychologia       Date:  2008-03-06       Impact factor: 3.139

3.  Preparing for preventive clinical trials: the Predict-HD study.

Authors:  Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner
Journal:  Arch Neurol       Date:  2006-06

4.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

Authors:  Andrea Ciarmiello; Milena Cannella; Secondo Lastoria; Maria Simonelli; Luigi Frati; David C Rubinsztein; Ferdinando Squitieri
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

5.  Onset and rate of striatal atrophy in preclinical Huntington disease.

Authors:  E H Aylward; B F Sparks; K M Field; V Yallapragada; B D Shpritz; A Rosenblatt; J Brandt; L M Gourley; K Liang; H Zhou; R L Margolis; C A Ross
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

6.  Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.

Authors:  Ferdinando Squitieri; Milena Cannella; Maria Simonelli; Jenny Sassone; Tiziana Martino; Eugenio Venditti; Andrea Ciammola; Claudio Colonnese; Luigi Frati; Andrea Ciarmiello
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

7.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

8.  Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.

Authors:  Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Chris Frost; David G MacManus; Roger A Barker; Nick C Fox; Sarah J Tabrizi
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

9.  Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Authors:  N C Fox; R S Black; S Gilman; M N Rossor; S G Griffith; L Jenkins; M Koller
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

Review 10.  Pharmaceutical, cellular and genetic therapies for Huntington's disease.

Authors:  Olivia J Handley; Jenny J Naji; Stephen B Dunnett; Anne E Rosser
Journal:  Clin Sci (Lond)       Date:  2006-01       Impact factor: 6.124

View more
  35 in total

1.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

2.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 3.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 4.  Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies.

Authors:  A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-22       Impact factor: 3.825

5.  Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease.

Authors:  F Sampedro; S Martínez-Horta; J Perez-Perez; A Horta-Barba; J Martin-Lahoz; A Alonso-Solís; I Corripio; B Gomez-Anson; J Kulisevsky
Journal:  AJNR Am J Neuroradiol       Date:  2019-09       Impact factor: 3.825

6.  Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease.

Authors:  Zhihong Guo; Gay Rudow; Olga Pletnikova; Kari-Elise Codispoti; Brent A Orr; Barbara J Crain; Wenzhen Duan; Russell L Margolis; Adam Rosenblatt; Christopher A Ross; Juan C Troncoso
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

7.  Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen
Journal:  J Huntingtons Dis       Date:  2013

8.  The accuracy of linear indices of ventricular volume in pediatric hydrocephalus: technical note.

Authors:  Dustin K Ragan; Jonathon Cerqua; Tiffany Nash; Robert C McKinstry; Joshua S Shimony; Blaise V Jones; Francesco T Mangano; Scott K Holland; Weihong Yuan; David D Limbrick
Journal:  J Neurosurg Pediatr       Date:  2015-03-06       Impact factor: 2.375

9.  Cognitive reserve and brain reserve in prodromal Huntington's disease.

Authors:  Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen
Journal:  J Int Neuropsychol Soc       Date:  2013-05-23       Impact factor: 2.892

10.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.